Nasus Pharma Ltd filed a Form F-1 registration statement for an initial public offering on 2025-07-09. It has amended it 2 times. It filed its final prospectus on 2025-08-14, at a public offering price of $8.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our Ordinary Shares are listed on the NYSE American LLC, or NYSE American, under the symbol “NSRX”.From the F-1 filed 2026-03-02
Shares offered
We are offering 1,250,000 ordinary shares, no par value, or Ordinary Shares, at a public offering price of $8.00 per Ordinary Share.From the 424B4 filed 2025-08-14
Offering price
We are offering 1,250,000 ordinary shares, no par value, or Ordinary Shares, at a public offering price of $8.00 per Ordinary Share.From the 424B4 filed 2025-08-14
Use of proceeds
We intend to use the net proceeds from the February 2026 Private Placement for our ongoing clinical development of NS002 for anaphylaxis treatment, the initiation of first-in-human studies for other products in our pipeline, working capital and general corporate purposes.From the F-1 filed 2026-03-02
Net loss or income
Our net loss for the years ended December 31, 2024 and 2023 were $1.5 million and $1.1 million, respectively, and $1.3 million and $0.9 million for the six months ended June 30, 2025 and 2024, respectively.From the F-1 filed 2026-03-02
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-07-09 | Registration statement filed (foreign issuer) | F-1 |
| 2025-07-28 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-08-07 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-08-14 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-03-02 | Registration statement filed (foreign issuer) | F-1 |
Tools for this story
Each opens in a new tab, filled in for Nasus Pharma Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.